Dr. Jessica Grossman

Jessica Grossman, MD is a leader in women’s health. Currently, she serves as the CEO of IgGenix. Previously, she was CEO of Medicines360, a nonprofit pharmaceutical company. Dr. Grossman has been a board member of Medicines360 since 2011. Medicines360 and its partner Allergan globally commercialize LILETTA®, a 52mg hormonal IUD that received FDA approval in 2015.

Prior to joining Medicines360, Dr. Grossman served as president and Founding CEO of Sense4Baby, Inc., where she closed a multi-million dollar Series A investment and within 18 months of joining the organization led the company to a successful acquisition following FDA clearance, CE mark, and early commercialization.

Dr. Grossman was also Founder and President of Gynesonics, an early stage medical device company focused on minimally invasive solutions for women’s health where she raised over $22 million in venture capital financing. Under her leadership, she invented and developed the first intrauterine ultrasound guided radiofrequency ablation device for fibroid tumors.

She has also been a Medical Director at Ethicon Endo-Surgery, part of the Johnson and Johnson family of companies. Dr. Grossman holds numerous patents and has published several peer reviewed articles. She has performed research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School.

She earned her MD at Thomas Jefferson University and her undergraduate degree with honors from Brandeis University.